-
Morgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks
Monday, July 27, 2015 - 12:24pm | 350Read More...In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene Corporation (NASDAQ: CELG) but boosted his price target from $107 to $134. Celgene opened the day above Harrison's $134 price target, but has fallen more than 2 percent to...
-
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk
Monday, July 27, 2015 - 8:07am | 316Read More...In a report published Monday, Morgan Stanley analyst Matthew Harrison downgraded the rating on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) to Equal-weight, while raising the price target from $77 to $126. The analyst believes that the stock valuation is "stretch" and that there is...
-
Celgene-Receptos: How Wall Street Is Reacting
Wednesday, July 15, 2015 - 8:25am | 542Read More...Shares of Receptos Inc (NASDAQ: RCPT) were trading higher by more than 10 percent during Wednesday's pre-market session after it received an acquisition offer on Tuesday by Celgene Corporation (NASDAQ: CELG) for $232 per share, valuing the entire transaction at $7.2 billion. Several of Wall...
-
Morgan Stanley Just Cut Juno Therapeutics' Price Target
Tuesday, June 30, 2015 - 3:42pm | 285Read More...Shares of Juno Therapeutics Inc (NASDAQ: JUNO) surged on Tuesday, after the company announced a decade-long collaboration agreement with Celgene Corporation (NASDAQ: CELG). Morgan Stanley analysts Matthew Harrison and Matthew S Pommer updated their model for Juno to reflect the new deal, which...
-
Analysts Diverge On Celgene's Deal With Juno Therapeutics
Tuesday, June 30, 2015 - 11:37am | 381Read More...Whether Celgene Corporation (NASDAQ: CELG) went too far in its $1 billion development deal with Juno Therapeutics Inc (NASDAQ: JUNO) is a matter for speculation. Celgene unveiled an agreement late Monday in which it will pay Juno $150 million and acquire about $850 million in Juno shares in...
-
Morgan Stanley: Market's Reaction To Linger For Alexion Pharmaceuticals
Thursday, May 7, 2015 - 4:03pm | 242Read More...Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) shares are likely to suffer lingering ill effects from its $8.4 billion plan to acquire Synageva Biopharma Corp. (NASDAQ: GEVA), an analyst said Thursday. Even with a recent recovery, Alexion remains off more than 10 percent since the cash-and-stock deal...
-
What's Wall Street Been Saying About Gilead Lately?
Wednesday, April 29, 2015 - 12:34pm | 588Read More...Gilead Sciences, Inc. (NASDAQ: GILD) is scheduled to release its first quarter results on Thursday after market close. The Estimize consensus earnings per share estimate (based on 137 estimates) is $2.48 on revenue of $7.049 billion. This compares to the Wall Street Consensus earnings per...
-
Analysts See Biogen Catalyst Coming On Friday
Tuesday, March 17, 2015 - 1:18pm | 282Read More...Biogen Idec Inc (NASDAQ: BIIB) is likely to present favorable data Friday on its prospective treatment for Alzheimer's disease, according to a couple of analysts. The company will issue results of a Phase Ib study of its monoclonal antibody BIIB037 at a conference in Nice, France. Its...
-
Analyst: 'Mess Continues' With Amgen Neupogen Competitor
Monday, March 9, 2015 - 3:16pm | 386Read More...Amgen, Inc. (NASDAQ: AMGN) will face competition for its Neupogen chemotherapy treatment from biotechnology, but exactly when a newly approved rival comes to market, and at what price, remains uncertain, an analyst said Monday. Novartis AG's (NYSE: NVS) Sandoz unit obtained U.S. regulatory...
-
Regeneron's Expanded Pipeline Not A Concern For Morgan Stanley
Wednesday, February 11, 2015 - 11:26am | 152Read More...Morgan Stanley on Wednesday issued a report on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) after the company reported guidance that was below estimates. Regeneron is currently rated as Overweight with a price target of $499.00. Analysts Matthew Harrison, Matthew Pommer and Amy Le wrote, "the...
-
Morgan Stanley Upgrades Gilead Sciences, Says It Will Maintain 75% Market Share
Monday, December 29, 2014 - 4:08pm | 145Read More...Morgan Stanley upgraded Gilead Sciences, Inc. (NASDAQ: GILD) from Equal-weight to Overweight on Monday and raised its price target from $100 to $104. Analyst Matthew Harrison felt that price fears were exaggerated. Analysts at Bank of America and Deutsche Bank predicted a possible price war...
-
These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market
Friday, December 12, 2014 - 12:44pm | 365Read More...A recent report by Morgan Stanley predicts a greater than 40 percent growth in the Hepatitis C (HCV) market in 2015. Projections indicate that the HCV market could be worth $15 billion in upcoming years, with two-thirds of treatment occurring in the United States. HCV Forerunners Gilead And...
-
The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley
Thursday, December 11, 2014 - 2:02pm | 355Read More...In its recent annual Big Debates report, Morgan Stanley named Biogen Idec Inc (NASDAQ: BIIB) as its top large-cap biotech stock pick for 2015. Analysts are impressed with Biogen’s robust drug pipeline and feel that very little of the company’s potential is currently priced into...
-
UPDATE: Morgan Stanley Raises PT on Gilead Sciences Following AlphaWise Survey
Tuesday, December 9, 2014 - 12:10pm | 121Read More...In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Gilead Sciences (NASDAQ: GILD), and raised the price target from $81.00 to $100.00. In the report, Morgan Stanley noted, “Our avg. price/patient for US HCV rises ~15%, offset by ~5% cut in...
-
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Inc Following DME Doc Event
Thursday, September 18, 2014 - 10:51am | 133Read More...In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Regeneron Pharmaceuticals Inc (NASDAQ: REGN), but removed the $310.00 price target. In the report, Morgan Stanley noted, “We hosted two retina specialists to discuss trends in DME treatment...
